Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Santoro, Armando" or (type any "bookEditor issueEditor" and editor="Santoro, Armando")

Add to list
- Journal Article
- A1
- open access
Phase I/IIa trial of BMS-986148, an anti-mesothelin antibody–drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors

Sylvie Rottey (UGent) , Jeffrey Clarke, Kyaw Aung, Jean-Pascal Machiels, Ben Markman, Kimberley M. Heinhuis, Michael Millward, Martijn Lolkema, Sandip Pravin Patel, Paul de Souza, et al.

(2022) CLINICAL CANCER RESEARCH. 28(1). p.95-105
Add to list
- Conference Paper
- C3
- open access
A phase 1B multi-tumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors : results of the triple-negative breast cancer, ovarian cancer, and endometrial cancer cohorts

Ira Winer, Akhila Wimalasingham, Joaquina Baranda, Armando Santoro, Kristen Spencer, Capucine Baldini, Linda Duska, Vivek Subbiah, Sandip Patel, Polina Khrizman, et al.

(2021) JOURNAL FOR IMMUNOTHERAPY OF CANCER. In Journal for Immunotherapy of Cancer 9(Supplement 2). p.A562-A562
Add to list
- Journal Article
- A1
- open access
Avelumab in combination regimens for relapsed/refractory DLBCL : results from the phase Ib JAVELIN DLBCL study

Eliza A. Hawkes, Tycel Phillips, Lihua Elizabeth Budde, Armando Santoro, Nakhle S. Saba, Fernando Roncolato, Gareth P. Gregory, Gregor Verhoef, Fritz Offner (UGent) , Cristina Quero, et al.

(2021) TARGETED ONCOLOGY. 16(6). p.761-771
Add to list
Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma

Nicola Personeni, Laura Giordano, Giovanni Abbadessa, Camillo Porta, Ivan Borbath, Bruno Daniele, Jean-Luc Van Laethem, Hans Van Vlierberghe (UGent) , Joerg Trojan, Enrico N. De Toni, et al.

(2017) ONCOTARGET. 8(9). p.14408-14415
Add to list
- Conference Paper
- C3
Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Robert W Chen, Stephen Maxted Ansel, Pier Luigi Zinzani, Jeffrey L Vacirca, Armando Lopez-Guillermo, Martin Hutchings, Wojciech Jurczak, Georg Hess, Steven Le Gouill, Fritz Offner (UGent) , et al.

(2017) JOURNAL OF CLINICAL ONCOLOGY. 35(suppl. 15).
Add to list
- Journal Article
- A1
- open access
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

Lorenza Rimassa, Giovanni Abbadessa, Nicola Personeni, Camillo Porta, Ivan Borbath, Bruno Daniele, Stefania Salvagni, Jean-Luc Van Laethem, Hans Van Vlierberghe (UGent) , Jörg Trojan, et al.

(2016) ONCOTARGET. 7(45). p.72622-72633
Add to list
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Armando Santoro, Lorenza Rimassa, Ivan Borbath, Bruno Daniele, Stefania Salvagni, Jean Luc Van Laethem, Hans Van Vlierberghe (UGent) , Jörg Trojan, Frank T Kolligs, Alan Weiss, et al.

(2013) LANCET ONCOLOGY. 14(1). p.55-63
Add to list
Sorafenib in advanced hepatocellular carcinoma

Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frederic Blanc, Andre Cosme de Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner, et al.

(2008) NEW ENGLAND JOURNAL OF MEDICINE. 359(4). p.378-390

Academic Bibliography

Phase I/IIa trial of BMS-986148, an anti-mesothelin antibody–drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors

A phase 1B multi-tumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors : results of the triple-negative breast cancer, ovarian cancer, and endometrial cancer cohorts

Avelumab in combination regimens for relapsed/refractory DLBCL : results from the phase Ib JAVELIN DLBCL study

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma

Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Sorafenib in advanced hepatocellular carcinoma

Contents

Support

Contact